Notice of Insider Transaction

Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics, Inc., sold 10,773 shares of common stock on June 17, 2026, for a price of $3.155 per share. The sale was conducted to satisfy tax obligations on vested restricted stock units. Following the transaction, Halladay owns 702,829 shares. The filing also includes a limited power of attorney granted by Halladay, authorizing attorneys-in-fact to execute necessary SEC filings on his behalf.